MARKET NEWS

Sanofi & Alnylam Conclude Research & Option Phase of 2014 Rare Disease Alliance
Neon Therapeutics Announces Completion of Enrollment in Phase 1b Clinical Trial
Thermo Fisher Scientific Announces Collaboration to Advance Biopharmaceutical Characterization & Monitoring Methods
XOMA Acquires Royalty Rights to Five Hematology Candidates
Bellerophon Announces Agreement With FDA on Regulatory Approval Pathway for INOpulse
SomaLogic Announces New Collaboration With Janssen Research & Development

  FEATURED EDITORIAL

  COMPANY PROFILE

Portal Instruments, a clinical-stage medical device company is developing a next- generation needle-free drug injection platform to transform the drug delivery experience for patients suffering from chronic diseases, such as ulcerative colitis, multiple sclerosis, rheumatoid arthritis, and psoriasis. Today, patients suffering from many chronic conditions have access to biologic drugs that can greatly improve their well-being. Unfortunately, those drugs must often be self-injected via a needle and syringe, which can lead to patient anxiety and uncertainty. In some cases, patients may refuse treatment or skip injections and then might not be able to reach the outcomes that they wish. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Industry Trends: Vigilance is Critical for Future Success

Industry Trends: Vigilance is Critical for Future Success

Peter Soelkner says there will always be a wide variety of trends influencing our industry and we see no reason why this will not continue well into the future.

GeneDesign Joins Ajinomoto Bio-Pharma Services & Opens Oligonucleotide API Development Center

GeneDesign Joins Ajinomoto Bio-Pharma Services & Opens Oligonucleotide API Development Center

Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, recently announced that GeneDesign, Inc. has joined the global organization.

BioAtla & BeiGene Form Worldwide Development & Commercialization Collaboration

BioAtla & BeiGene Form Worldwide Development & Commercialization Collaboration

BioAtla , LLC and BeiGene, Ltd. recently announced the two companies have entered into a global co-development and collaboration agreement for the development, manufacturing, and commercialization of BioAtla’s investigational CAB CTLA-4 antibody (BA3071).

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 24 – Inhalation Drug Delivery
May 1 – Formulation Development